论文部分内容阅读
冠心病是目前我国最常见的心血管疾病,非ST段抬高急性冠状动脉综合征(non-ST-segment elevation acute coronary syndrome,NSTE-ACS)并发症多、病死率高。氯吡格雷联合阿司匹林的双联抗血小板治疗(DAPT)是预防经皮冠状动脉支架置入术(PCI)后心血管缺血事件再发的标准治疗。根据近期研究,国外指南~[1]推荐:对于所有中高缺血风险的患者,无论初始治疗如何,即使前期已使用了氯吡格雷进行预治疗,若无禁忌证,建议
Coronary heart disease is the most common cardiovascular disease in our country. There are many complications of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) with high mortality. Dual antiplatelet therapy (DAPT) of clopidogrel in combination with aspirin is the standard treatment for the prevention of recurrent cardiovascular events following percutaneous coronary stenting (PCI). According to recent studies, foreign guidelines ~ [1] Recommendation: For all patients with high risk of ischemic stroke, regardless of the initial treatment, even if pre-treatment with clopidogrel has been used in the previous period, if there is no contraindication, it is recommended